A health products maker which is listed on the New York Stock Exchange has agreed to acquire a US counterpart, including its UK base in Nottingham.
Catalent is to snap up Juniper Pharmaceuticals, which is listed on the NASDAQ, together with its Juniper Pharma Services division in the East Midlands.
The acquisition of Juniper is subject to certain customary closing conditions, including that a majority of Juniper’s shares are tendered into the offer, and is expected to close in the first quarter of Catalent’s 2019 fiscal year, which began on 1 July.
Catalent Oral Drug Delivery president Jonathan Arnold said: “Juniper’s scientific expertise in early-phase product development and supply will help our customers unlock the full potential of their molecules and provide better treatments to patients, faster.
“Juniper’s proven solutions and capabilities will further support Catalent’s strategic goal to be the most comprehensive partner for pharmaceutical innovators.
“Juniper’s scientific expertise in early-phase product development and supply will help our customers unlock the full potential of their molecules and provide better treatments to patients, faster.”
To find out more about Juniper Pharma, including its recent strategic capital investment in oral solid dose services, please click here.
